All In Biotech

Drug Trial Radar · NCT05743634

A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

A Phase I/II,Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Safety,Efficacy and Immunogenicity of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

Last checked: Nov 19, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Mar 22, 2022

Primary completion

Feb 13, 2023

Study completion Feb 13, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety,immunogenicity and efficacy of YY001 for the treatment of moderate to severe glabellar lines in male and female subjects of Chinese origin. The study has been designed to test the safety,efficacy,immunogenicity of YY001,and compare to onabotulinumtoxinA (BOTOX®) and placebo, in improving the appearance of moderate to severe glabellar lines.

Conditions

  • Moderate to Severe Glabellar Lines

Interventions

  • YY001Biological

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

  • OnabotulinumtoxinABiological

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

  • PlaceboBiological

    Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase1:The incidence rate of adverse events and severe adverse events within 28 days after injectionTime frame: Within 28 days
  2. Phase1:The incidence rate of injection site reaction within 28 days after injectionTime frame: Within 28 days
  3. Phase1:The incidence rate of abnormal lab findings which have clinical significance within 28 days after injectionTime frame: Within 28 days
  4. Phase2:The response rate will be evaluated at 28 days by investigator at maximum frownTime frame: 28 days
  5. Phase2:The incidence rate of adverse events and severe adverse events within 12 weeks after injectionTime frame: within 12 weeks
  6. Phase2:The incidence rate of injection site reaction within 12 weeks after injectionTime frame: within 12 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • The First affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Nanfang Hospital,Southern Medical University

    Guangzhou, Guangdong, China

  • Shanghai Ninth People's Hospital,Shanghai JiaoTong University school of Medicine

    Shanghai, Shanghai Municipality, China

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.